The first European patients are set to receive Kite Pharma’s CAR-T cancer therapy after the US biotech started EU trials. The first patient to receive the treatment known as axicabtagene ...

Kite Pharma has its nose ahead of Novartis ... which could form the basis of a filing next year for its CRL019 CAR-T therapy in adults and children with relapsed/refractory B-cell acute ...

Real-world outcomes of patients with relapsed/refractory multiple myeloma treated with the chimeric antigen receptor (CAR) ...

Kite, a Gilead company GLD, announced that the Food & Drug Administration granted accelerated approval to Tecartus, a CAR T cell therapy for the treatment of adult patients with mantle cell lymphoma.

CAR-T cell therapy is a regenerative immunotherapy in ... The study was partly funded by Kite, a Gilead company, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Comprehensive Cancer ...

“CAR T therapy is the first treatment in more than ... Rejeski has received research funding from Kite/Gilead; is a consultant for Kite/Gilead and Bristol Myers Squibb/Celgene; has received ...

The US FDA has granted Kite’s Yescarta (axicabtagene ciloleucel) a Regenerative Medicine Advanced Therapy (RMAT) designation ...

Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been co-developing the CAR-T therapy in China. Its biopharmaceutical platform, Henlius is developing biosimilars ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma. Fosun ...